🇺🇸 Clopidogrel+acetylsalicylic acid in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 12

Most-reported reactions

1. Hyponatraemia — 2 reports (16.67%)
2. Renal Failure Acute — 2 reports (16.67%)
3. Acute Pulmonary Oedema — 1 report (8.33%)
4. Angina Pectoris — 1 report (8.33%)
5. Angioedema — 1 report (8.33%)
6. Back Pain — 1 report (8.33%)
7. Blood Glucose Abnormal — 1 report (8.33%)
8. Blood Pressure Fluctuation — 1 report (8.33%)
9. Cardiac Disorder — 1 report (8.33%)
10. Chest Pain — 1 report (8.33%)

Source database →

Frequently asked questions

Is Clopidogrel+acetylsalicylic acid approved in United States?

Clopidogrel+acetylsalicylic acid does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Clopidogrel+acetylsalicylic acid in United States?

Rigshospitalet, Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.